P02-027 - Quality of life in CAPS treated by Canakinumab
نویسندگان
چکیده
Methods Patients were those first included in the pivotal (D2304) and in the extension (D2306) Canakinumab/CAPS study [1] and followed in the reference center for autoinflammatory diseases at Bicêtre Hospital (Paris). All carried a heterozygous mutation in the NLPR3 gene and had received Canakinumab (dose of 150 mg every 8 weeks or 2mg/kg for patient weight under 40kg). All patients had been followed prospectively and their quality of life had been evaluated regularly with generic questionnaires: Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F), 36-item Short Form health survey (SF-36) and Health Assessment Questionnaire (HAQ) for adults. Furthermore supplementary questions regarding their social activities and how they deal with their treatment were added.
منابع مشابه
P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
Objectives The objectives of the study were to describe the kinetics of canakinumab and dynamics of binding IL-1b in CAPS patients; to determine if these are different in 2and 3-year-old children versus older children and adults; and to explore the impact of CAPS phenotype (Muckle-Wells Syndrome [MWS], Familial Cold Autoinflammatory Syndrome [FCAS], Neonatal-Onset Multisystem Inflammatory Disea...
متن کاملP02-033 - CAPS diagnosis and treatment in an Israeli family
Case Report We confirmed the Muckle-Wells syndrome phenotype of CAPS by NLRP3 genetic testing in a three generation family of Turkish Jewish origin, previously diagnosed with familial Behcet disease due to the presence of mucosal ulcers in several family members with the finding of the HLA-B51 antigen in at least one family member. Eight family members including a deceased grandfather, 4 of his...
متن کاملP02-020 - CAPS in Turkish children: treatment with ANTI IL1
Case Report Results All of our patients had symptoms within the first 3 months of life. All had fever, urticaria and persistant labaratory inflammation. All except one patient had failure to thrive. Except for the one patient with Muckle Wells syndrome all had neurological features ranging from headache to convulsions, hydrocephalus, cognitive dysfunction.Two patients, one without a mutation, h...
متن کامل“Daily life of CAPS patients treated with canakinumab (Ilaris®) : data from the French observational study - ENVOL Study”
Methods We targeted the 70-80 patients ever treated for CAPS in France, at least once and even during a clinical trial. Patients’ (parents end caregivers) gave their informed consent to enter the study. Investigators were known experts in the field of CAPS in France who accepted to take part in the study. Data were collected through questionnaires by phone interviews and medical chart reviews, ...
متن کاملSustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
INTRODUCTION To assess the effect of canakinumab, a fully human anti-interleukin-1β antibody, on symptoms and health-related quality of life (HRQoL) in patients with cryopyrin-associated periodic syndrome (CAPS). METHODS In this 48-week, phase 3 study, patients with CAPS received canakinumab 150 mg subcutaneously at 8-week intervals. All patients (n = 35) received canakinumab during weeks 1 t...
متن کامل